FR22C1058I2 - TABLET FORMULATION OF 2-FLUORO-N-METHYL-4-[7-(QUINOLINE -6-YLMETHYL) IMIDAZO[1,2-B][1,2,4]TRIAZINE -2-YL]BENZAMIDE - Google Patents

TABLET FORMULATION OF 2-FLUORO-N-METHYL-4-[7-(QUINOLINE -6-YLMETHYL) IMIDAZO[1,2-B][1,2,4]TRIAZINE -2-YL]BENZAMIDE

Info

Publication number: FR22C1058I2
Authority: FR; France
Prior art keywords: imidazo; benzamide; ylmethyl; quinoline; triazine
Prior art date: 2014-07-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR22C1058C

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-07-25

Filing date

2022-12-06

Publication date

2023-11-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53762251&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1058(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2022-12-06 Application filed filed Critical

2023-01-06 Publication of FR22C1058I1 publication Critical patent/FR22C1058I1/en

2023-11-17 Application granted granted Critical

2023-11-17 Publication of FR22C1058I2 publication Critical patent/FR22C1058I2/en

Status Active legal-status Critical Current

Links

LIOLIMKSCNQPLV-UHFFFAOYSA-N 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1C1=NN2C(CC=3C=C4C=CC=NC4=CC=3)=CN=C2N=C1 LIOLIMKSCNQPLV-UHFFFAOYSA-N 0.000 title 1
239000007916 tablet composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

FR22C1058C 2014-07-25 2022-12-06 TABLET FORMULATION OF 2-FLUORO-N-METHYL-4-[7-(QUINOLINE -6-YLMETHYL) IMIDAZO[1,2-B][1,2,4]TRIAZINE -2-YL]BENZAMIDE Active FR22C1058I2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462028865P	2014-07-25	2014-07-25
PCT/IB2015/055561 WO2016012963A1 (en)	2014-07-25	2015-07-22	Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

Publications (2)

Publication Number	Publication Date
FR22C1058I1 FR22C1058I1 (en)	2023-01-06
FR22C1058I2 true FR22C1058I2 (en)	2023-11-17

Family

ID=53762251

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR22C1058C Active FR22C1058I2 (en)	2014-07-25	2022-12-06	TABLET FORMULATION OF 2-FLUORO-N-METHYL-4-[7-(QUINOLINE -6-YLMETHYL) IMIDAZO[1,2-B][1,2,4]TRIAZINE -2-YL]BENZAMIDE

Country Status (30)

Country	Link
US (4)	US10085993B2 (en)
EP (2)	EP3848376A1 (en)
JP (3)	JP6770946B2 (en)
KR (2)	KR102581121B1 (en)
CN (2)	CN115364061A (en)
AR (1)	AR101286A1 (en)
AU (4)	AU2015293539A1 (en)
CA (1)	CA2954840A1 (en)
CL (1)	CL2017000180A1 (en)
CO (1)	CO2017000586A2 (en)
DK (1)	DK3172209T3 (en)
EA (2)	EA202191301A1 (en)
EC (1)	ECSP17011672A (en)
ES (1)	ES2857523T3 (en)
FR (1)	FR22C1058I2 (en)
GT (1)	GT201700007A (en)
HU (2)	HUE053346T2 (en)
IL (1)	IL250166B (en)
JO (1)	JO3618B1 (en)
MX (2)	MX2017001177A (en)
MY (1)	MY187276A (en)
NZ (1)	NZ728089A (en)
PE (1)	PE20170523A1 (en)
PH (1)	PH12017500121A1 (en)
PL (1)	PL3172209T3 (en)
PT (1)	PT3172209T (en)
SG (2)	SG11201700147SA (en)
SI (1)	SI3172209T1 (en)
TW (2)	TW202200148A (en)
WO (1)	WO2016012963A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2834246B1 (en)	2012-04-03	2021-07-28	Novartis AG	Combination products with tyrosine kinase inhibitors and their use
NZ728089A (en) *	2014-07-25	2024-01-26	Novartis Ag	Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
IL264593B (en)	2016-08-10	2022-07-01	Hoffmann La Roche	Pharmaceutical compositions comprising akt protein kinase inhibitors
WO2022007752A1 (en) *	2020-07-06	2022-01-13	苏州晶云药物科技股份有限公司	New crystal form of benzamide compound and dihydrochloride thereof, and preparation method therefor
WO2023138492A1 (en) *	2022-01-19	2023-07-27	南京明德新药研发有限公司	Composition of pyrimidine group-containing tricyclic compound, preparation method therefor and use thereof
WO2023249994A1 (en) *	2022-06-22	2023-12-28	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2465565A1 (en) *	2003-06-12	2004-12-12	Warner-Lambert Company Llc	Pharmaceutical compositions of atorvastatin
US20070042034A1 (en) *	2005-07-22	2007-02-22	Myriad Genetics, Incorporated	High drug load formulations and dosage forms
CA2621273C (en)	2005-09-12	2014-07-29	Actelion Pharmaceuticals Ltd	Stable pharmaceutical composition comprising a pyrimidine-sulfamide
CA2563690C (en) *	2006-10-12	2014-10-07	Pharmascience Inc.	Pharmaceutical compositions comprising intra- and extra- granular fractions
DK3034075T3 (en)	2006-11-22	2018-10-22	Incyte Holdings Corp	IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASEI INHIBITORS
LT2300455T (en) *	2008-05-21	2017-11-10	Incyte Holdings Corporation	Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
EP3566697A1 (en) *	2009-11-09	2019-11-13	Wyeth LLC	Tablet formulations of neratinib maleate
JP5849312B2 (en) *	2010-05-21	2016-01-27	インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅＨｏｌｄｉｎｇｓＣｏｒｐｏｒａｔｉｏｎ	Topical formulation of JAK inhibitor
CA2804506C (en)	2010-07-06	2018-08-21	Janssen Pharmaceutica Nv	Formulation for co-therapy treatment of diabetes
MX369518B (en)	2012-08-16	2019-11-11	Novartis Ag	Combination of pi3k inhibitor and c-met inhibitor.
NZ728089A (en) *	2014-07-25	2024-01-26	Novartis Ag	Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

2015
- 2015-07-22 NZ NZ728089A patent/NZ728089A/en unknown
- 2015-07-22 US US15/328,661 patent/US10085993B2/en active Active
- 2015-07-22 EA EA202191301A patent/EA202191301A1/en unknown
- 2015-07-22 MY MYPI2017700061A patent/MY187276A/en unknown
- 2015-07-22 HU HUE15744702A patent/HUE053346T2/en unknown
- 2015-07-22 CN CN202210949714.1A patent/CN115364061A/en active Pending
- 2015-07-22 CN CN201580052264.4A patent/CN106714784A/en active Pending
- 2015-07-22 AU AU2015293539A patent/AU2015293539A1/en not_active Abandoned
- 2015-07-22 PL PL15744702T patent/PL3172209T3/en unknown
- 2015-07-22 KR KR1020177004939A patent/KR102581121B1/en active IP Right Grant
- 2015-07-22 SG SG11201700147SA patent/SG11201700147SA/en unknown
- 2015-07-22 WO PCT/IB2015/055561 patent/WO2016012963A1/en active Application Filing
- 2015-07-22 PE PE2017000097A patent/PE20170523A1/en unknown
- 2015-07-22 EA EA201790259A patent/EA039220B1/en unknown
- 2015-07-22 SI SI201531507T patent/SI3172209T1/en unknown
- 2015-07-22 CA CA2954840A patent/CA2954840A1/en active Pending
- 2015-07-22 MX MX2017001177A patent/MX2017001177A/en unknown
- 2015-07-22 EP EP20210458.4A patent/EP3848376A1/en active Pending
- 2015-07-22 ES ES15744702T patent/ES2857523T3/en active Active
- 2015-07-22 PT PT157447020T patent/PT3172209T/en unknown
- 2015-07-22 DK DK15744702.0T patent/DK3172209T3/en active
- 2015-07-22 EP EP15744702.0A patent/EP3172209B1/en active Active
- 2015-07-22 SG SG10201900648SA patent/SG10201900648SA/en unknown
- 2015-07-22 JP JP2017504062A patent/JP6770946B2/en active Active
- 2015-07-22 KR KR1020237031767A patent/KR20230136693A/en not_active Application Discontinuation
- 2015-07-23 AR ARP150102336A patent/AR101286A1/en unknown
- 2015-07-23 TW TW110109338A patent/TW202200148A/en unknown
- 2015-07-23 TW TW104123937A patent/TWI724993B/en active
- 2015-07-23 JO JOP/2015/0174A patent/JO3618B1/en active
2017
- 2017-01-17 IL IL250166A patent/IL250166B/en active IP Right Grant
- 2017-01-20 PH PH12017500121A patent/PH12017500121A1/en unknown
- 2017-01-24 CO CONC2017/0000586A patent/CO2017000586A2/en unknown
- 2017-01-24 CL CL2017000180A patent/CL2017000180A1/en unknown
- 2017-01-25 GT GT201700007A patent/GT201700007A/en unknown
- 2017-01-25 MX MX2021000595A patent/MX2021000595A/en unknown
- 2017-02-24 EC ECIEPI201711672A patent/ECSP17011672A/en unknown
2018
- 2018-07-23 AU AU2018207947A patent/AU2018207947A1/en not_active Abandoned
- 2018-09-18 US US16/134,162 patent/US10596178B2/en active Active
2020
- 2020-02-07 AU AU2020200912A patent/AU2020200912B2/en active Active
- 2020-02-13 US US16/789,655 patent/US20210113569A1/en not_active Abandoned
- 2020-03-27 JP JP2020058164A patent/JP7002587B2/en active Active
2021
- 2021-04-23 AU AU2021202500A patent/AU2021202500A1/en not_active Abandoned
- 2021-12-15 US US17/644,473 patent/US20220249498A1/en active Pending
- 2021-12-24 JP JP2021211526A patent/JP2022046659A/en active Pending
2022
- 2022-12-06 FR FR22C1058C patent/FR22C1058I2/en active Active
- 2022-12-19 HU HUS2200054C patent/HUS2200054I1/en unknown

Also Published As

Publication number	Publication date
US20220249498A1 (en)	2022-08-11
US10596178B2 (en)	2020-03-24
EP3172209A1 (en)	2017-05-31
JP2022046659A (en)	2022-03-23
TWI724993B (en)	2021-04-21
US20210113569A1 (en)	2021-04-22
AU2015293539A1 (en)	2017-02-02
US20190015418A1 (en)	2019-01-17
ES2857523T3 (en)	2021-09-29
IL250166A0 (en)	2017-03-30
AR101286A1 (en)	2016-12-07
PE20170523A1 (en)	2017-05-17
DK3172209T3 (en)	2021-02-22
KR20170039211A (en)	2017-04-10
GT201700007A (en)	2018-12-18
TW201613595A (en)	2016-04-16
CL2017000180A1 (en)	2017-09-15
AU2021202500A1 (en)	2021-05-20
CN115364061A (en)	2022-11-22
FR22C1058I1 (en)	2023-01-06
KR20230136693A (en)	2023-09-26
CA2954840A1 (en)	2016-01-28
US20170231997A1 (en)	2017-08-17
SG11201700147SA (en)	2017-02-27
HUS2200054I1 (en)	2023-01-28
AU2020200912B2 (en)	2021-01-28
CN106714784A (en)	2017-05-24
ECSP17011672A (en)	2018-03-31
SG10201900648SA (en)	2019-02-27
IL250166B (en)	2021-01-31
US10085993B2 (en)	2018-10-02
PT3172209T (en)	2021-02-11
TW202200148A (en)	2022-01-01
EP3848376A1 (en)	2021-07-14
EP3172209B1 (en)	2020-12-02
HUE053346T2 (en)	2021-06-28
BR112017000953A2 (en)	2017-11-14
KR102581121B1 (en)	2023-09-21
JP7002587B2 (en)	2022-01-20
PH12017500121A1 (en)	2017-05-29
MX2017001177A (en)	2017-05-01
EA202191301A1 (en)	2021-11-30
JP6770946B2 (en)	2020-10-21
AU2018207947A1 (en)	2018-08-09
PL3172209T3 (en)	2021-06-14
MX2021000595A (en)	2021-04-13
CO2017000586A2 (en)	2017-06-20
JP2017521469A (en)	2017-08-03
JO3618B1 (en)	2020-08-27
AU2020200912A1 (en)	2020-02-27
EA039220B1 (en)	2021-12-20
EA201790259A1 (en)	2017-06-30
WO2016012963A1 (en)	2016-01-28
NZ728089A (en)	2024-01-26
SI3172209T1 (en)	2021-03-31
JP2020114852A (en)	2020-07-30
MY187276A (en)	2021-09-17

Publication	Publication Date	Title
FR22C1058I2 (en)	2023-11-17	TABLET FORMULATION OF 2-FLUORO-N-METHYL-4-[7-(QUINOLINE -6-YLMETHYL) IMIDAZO[1,2-B][1,2,4]TRIAZINE -2-YL]BENZAMIDE
HK1256795A1 (en)	2019-10-04	Bipyrazolyl derivatives useful for the treatment of autoimmune diseases
IL254476A0 (en)	2017-11-30	Heterocyclylmethyl-thienouracile as antagonists of the adenosine-a2b-receptor
ZA201701814B (en)	2018-05-30	Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
HK1247203A1 (en)	2018-09-21	Substituted imidazo [1, 2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof
ZA201606075B (en)	2017-08-30	Pharmaceutical compositions of sitagliptin
PT3426294T (en)	2023-06-06	Pharmaceutical formulation
IL253177B (en)	2021-12-01	Pharmaceutical formulation
FR3039396B1 (en)	2017-08-11	BASE OF CONCENTRATED COSMETIC FORMULATION
HK1245653A1 (en)	2018-08-31	Pharmaceutical formulation
IL266537A (en)	2019-07-31	Pharmaceutical formulation
DK3362453T3 (en)	2022-06-07	CYCLIC ETHERERIVATIVES OF PYRAZOLO [1,5-A] PYRIMIDINE-3-CARBOXYAMIDE
ZA201807851B (en)	2022-04-28	Pharmaceutical formulation
GB201506755D0 (en)	2015-06-03	Novel pharmaceutical formulation
MA43166A (en)	2018-09-12	FORMULATION OF FVIII
GB201511246D0 (en)	2015-08-12	Pharmaceutical formulation
HK1244277A1 (en)	2018-08-03	New substituted triazolopyrimidines as anti-malarial agents
GB201604545D0 (en)	2016-05-04	Novel pharmaceutical formulation
TH1601001194A (en)	2017-10-19	New triazolo[4,5-d]pyrimidine derivatives
GB201407741D0 (en)	2014-06-18	Novel drug formulation
GB201400951D0 (en)	2014-03-05	Novel drug formulation